Gossamer Bio Inc

NASDAQ:GOSSUnited States

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The Company's product candidates include Seralutinib (GB002), GB004, GB5121 and GB7208. GB002 is an inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R) and c-KIT inhibitor in development for the treatment of pulmonary arterial hypertension (PAH). GB004 is a gut-targeted, oral small molecule being developed for the treatment of inflammatory bowel disease (IBD). GB5121 is an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK), in clinical development for the treatment of primary central nervous system lymphoma (PCNSL). GB7208 is an oral, small molecule, BTK inhibitor in preclinical development for the treatment of multiple sclerosis (MS).

Contact Information

Headquarters

3013 Science Park RdSAN DIEGO, CA, United States 92121-1101

Phone

858-922-0718

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer, Co-Founder

Faheem Hasnain

Chief Financial Officer, Chief Operating Officer

Bryan Giraudo

Executive Vice President - Regulatory Affairs

Caryn Peterson

Executive Vice President - Technical Operations and Administration

Christian Waage

Chief Scientific Officer

Laura Carter